UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 193

Sortiert nach

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2017-10, Vol.35 (30), p.3484-3515

2017

Volltextzugriff (PDF)

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2017-10, Vol.35 (28), p.3240-3261

2017

Volltextzugriff (PDF)

Antiemetics: ASCO Guideline Update

Journal of clinical oncology, 2020-08, Vol.38 (24), p.2782-2797

2020

Volltextzugriff (PDF)

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1608-1632

2020

Volltextzugriff (PDF)

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Journal of clinical oncology, 2017-11, Vol.35 (33), p.3737-3744

2017

Volltextzugriff (PDF)

Antiemetics: American Society of Clinical Oncology Focused Guideline Update

Journal of clinical oncology, 2016-02, Vol.34 (4), p.381-386

2016

Volltextzugriff (PDF)

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2011-11, Vol.29 (31), p.4189-4198

2011

Volltextzugriff (PDF)

Chemotherapy-Induced Nausea and Vomiting

The New England journal of medicine, 2008-06, Vol.358 (23), p.2482-2494

Hesketh, Paul J

2008

Volltextzugriff (PDF)

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

Cancer, 2016-08, Vol.122 (15), p.2418-2425

2016

Volltextzugriff (PDF)

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

Journal of clinical oncology, 2006-06, Vol.24 (18), p.2932-2947

2006

Volltextzugriff (PDF)

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Supportive care in cancer, 2017-01, Vol.25 (1), p.271-275

2017

Volltextzugriff (PDF)

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2822-2830

2005

Volltextzugriff (PDF)

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4112-4119

2003

Volltextzugriff (PDF)

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

PloS one, 2018-11, Vol.13 (11), p.e0208097-e0208097

2018

Volltextzugriff (PDF)

Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting

Supportive care in cancer, 2012-03, Vol.20 (3), p.653-656

2012

Volltextzugriff (PDF)

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

Supportive care in cancer, 2011-03, Vol.19 (Suppl 1), p.43-47

2011

Volltextzugriff (PDF)

Surgical Outcomes in a Large, Clinical, Low-Dose Computed Tomographic Lung Cancer Screening Program

The Annals of thoracic surgery, 2015-10, Vol.100 (4), p.1218-1223

2015

Volltextzugriff (PDF)

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1040-1091

2021

Volltextzugriff (PDF)

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

Cancer, 2003-05, Vol.97 (9), p.2290-2300

2003

Volltextzugriff (PDF)

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update

Supportive care in cancer, 2005-02, Vol.13 (2), p.80-84

2005

Volltextzugriff (PDF)

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Journal of clinical oncology, 2022-10, Vol.40 (28), p.3310-3322

2022

Volltextzugriff (PDF)

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Cancer, 2005-10, Vol.104 (7), p.1548-1555

2005

Volltextzugriff (PDF)

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

Supportive care in cancer, 2017-01, Vol.25 (1), p.277-288

2017

Volltextzugriff (PDF)

Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation

Supportive care in cancer, 2024-01, Vol.32 (1), p.53-53, Article 53

2024

Volltextzugriff (PDF)

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

The New England journal of medicine, 1999-01, Vol.340 (3), p.190-195

1999

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(164)

Publikationsform

Sprache

Englisch
(193)
Japanisch
(41)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(136)
Life Sciences & Biomedicine
(131)
Humans
(126)
Oncology
(93)
Female
(62)
Male
(60)
Vomiting - Chemically Induced
(58)
Vomiting - Prevention & Control
(54)
Antiemetics - Therapeutic Use
(51)
Middle Aged
(50)
Nausea - Chemically Induced
(48)
Aged
(46)
Nausea - Prevention & Control
(44)
Antineoplastic Agents - Adverse Effects
(43)
Biological And Medical Sciences
(43)
Chemotherapy
(39)
Adult
(38)
Medical Sciences
(38)
Nausea
(36)
Health Care Sciences & Services
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Antiemetics: ASCO Guideline Update

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Antiemetics: American Society of Clinical Oncology Focused Guideline Update

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Chemotherapy-Induced Nausea and Vomiting

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

Surgical Outcomes in a Large, Clinical, Low-Dose Computed Tomographic Lung Cancer Screening Program

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

Suchergebnisse filtern